New quinoxalinone inhibitors targeting secreted phospholipase A2 and α-glucosidase

References

• Savage PJ. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med 1996;124:123–6.
   PubMed Web of Science ®Google Scholar
• Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metabol 2009;5:150–9.
   PubMedGoogle Scholar
• Jensen MK, Bertoia ML, Cahill LE, et al. Novel metabolic biomarkers of cardiovascular disease. Nat Rev Endocrinol 2014;10:659–72.
   PubMed Web of Science ®Google Scholar
• Quach ND, Arnold RD, Cummings BS. Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease. Biochem Pharmacol 2014;90:338–48.
   PubMed Web of Science ®Google Scholar
• Guidet B, Piot O, Masliah J, et al. Secretory non-pancreatic phospholipase A2 in severe sepsis: relation to endotoxin, cytokines and thromboxane B2. Infection 1996;24:103–8.
   PubMed Web of Science ®Google Scholar
• Shoseyov D, Bibi H, Offer S, et al. Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A(2). Thorax 2005;60:747–53.
   PubMed Web of Science ®Google Scholar
• Moses GS, Jensen MD, Lue LF, et al. Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J Neuroinflamm 2006;3:28.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J 2012;33:2899–909.
   PubMed Web of Science ®Google Scholar
• Hui DY. Phospholipase A(2) enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol 2012;23:235–40.
   PubMed Web of Science ®Google Scholar
• Huggins KW, Boileau AC, Hui DY. Protection against diet-induced obesity and obesity-related insulin resistance in Group 1B PLA2-deficient mice. Am J Physiol Endocrinol Metabol 2002;283:E994–1001.
   PubMed Web of Science ®Google Scholar
• Shridas P, Zahoor L, Forrest KJ, et al. Group X secretory phospholipase A2 regulates insulin secretion through a cyclooxygenase-2-dependent mechanism. J Biol Chem 2014;289:27410–7.
   PubMed Web of Science ®Google Scholar
• Pettersson C, Fogelstrand L, Rosengren B, et al. Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia. J Intern Med 2008;264:155–65.
   PubMed Web of Science ®Google Scholar
• Reid RC. Inhibitors of secretory phospholipase A2 group IIA. Curr Med Chem 2005;12:3011–26.
   PubMed Web of Science ®Google Scholar
• Guichard G, Lena G, Boeglin J, et al. 1,3,5-Triazepan-2,6-diones as conformationally constrained dipeptide mimetics. In silico guided identification of sPLA2 inhibitors. Adv Exp Med Biol 2009;611:201–2.
   PubMed Web of Science ®Google Scholar
• Vasilakaki S, Barbayianni E, Magrioti V, et al. Inhibitors of secreted phospholipase A2 suppress the release of PGE2 in renal mesangial cells. Bioorg Med Chem 2016;24:3029–34.
   PubMed Web of Science ®Google Scholar
• Tundis R, Loizzo MR, Menichini F. Natural products as alpha-amylase and alpha-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update. Mini Rev Med Chem 2010;10:315–31.
   PubMed Web of Science ®Google Scholar
• Naumoff DG. Hierarchical classification of glycoside hydrolases. Biochem Biokhim 2011;76:622–35.
   PubMed Web of Science ®Google Scholar
• van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154–63.
   PubMed Web of Science ®Google Scholar
• Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;18(2):Cd003639. doi: 10.1002/14651858.CD003639.pub2
   Web of Science ®Google Scholar
• Dwek RA, Butters TD, Platt FM, Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov 2002;1:65–75.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ma S. Recent advances in synthetic alpha-glucosidase inhibitors. ChemMedChem 2017;12:819–29.
   PubMed Web of Science ®Google Scholar
• Tadera K, Minami Y, Takamatsu K, Matsuoka T. Inhibition of alpha-glucosidase and alpha-amylase by flavonoids. J Nutr Sci Vitaminol 2006;52:149–53.
   PubMed Web of Science ®Google Scholar
• Li YQ, Zhou FC, Gao F, et al. Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of alpha-glucosidase. J Agric Food Chem 2009;57:11463–8.
   PubMed Web of Science ®Google Scholar
• Jhong CH, Riyaphan J, Lin SH, et al. Screening alpha-glucosidase and alpha-amylase inhibitors from natural compounds by molecular docking in silico. BioFactors 2015;41:242–51.
   PubMed Web of Science ®Google Scholar
• Alasmari FA, Aljaber NA, Korrah MM. Synthesis and antimicrobial activities of some novel quinoxaline derivatives. Int J Adv Res Chem Sci (IJARCS) 2015;2(1):14–23.
   Google Scholar
• Haasnoot JG. Mononuclear, oligonuclear and polynuclear metal coordination compounds with 1, 2, 4-triazole derivatives as ligands. Coord Chem Rev 2000;200:131–85.
   Web of Science ®Google Scholar
• Pouralimardan O, Chamayou A-C, Janiak C, Hosseini-Monfared H. Hydrazone Schiff base-manganese (II) complexes: synthesis, crystal structure and catalytic reactivity. Inorg Chim Acta 2007;360:1599–608.
   Web of Science ®Google Scholar
• Mager HIX, Berends W. Investigations on pyrazine derivatives III: the preparation of 2,3-dihydroxypyrazine 5,6-dicarboxylic acid. Recueil Des Travaux Chimiques Des Pays-Bas 1958;77:842–9.
   Google Scholar
• Cheeseman GWH, Rafiq M. Quinoxalines and related compounds. Part VIII. The reactions of quinoxaline-2(1H)-ones and -2,3(1H,4H)-diones with hydrazine. J Chem Soc C: Org 1971;452–4.
   Web of Science ®Google Scholar
• Shiho D-i, Tagami S. Studies on compounds related to pyrazine. II. The reaction of 3-substituted-2-hydrazinoquinoxalines with carbonyl compounds. J Am Chem Soc 1960;82:4044–54.
   Web of Science ®Google Scholar
• Rashed N, El Massry AM, El Ashry ESH, et al. A facile synthesis of novel triazoloquinoxahnones and triazinoquinoxalinones. J Heterocycl Chem 1990;27:691–4.
   Web of Science ®Google Scholar
• Cheeseman GWH. 223. Quinoxalines and related compounds. Part VI. Substitution of 2,3-dihydroxyquinoxaline and its 1,4-dimethyl derivative. J Chem Soc 1962;5:1170–6.
   Web of Science ®Google Scholar
• Singer AG, Ghomashchi F, Le Calvez C, et al. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem 2002;277:48535–49.
   PubMed Web of Science ®Google Scholar
• Fraser H, Hislop C, Christie RM, et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE–/– mice. J Cardiovasc Pharmacol 2009;53:60–5.
   PubMed Web of Science ®Google Scholar
• Shaposhnik Z, Wang X, Trias J, et al. The synergistic inhibition of atherogenesis in apoE–/– mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res 2009;50:623–9.
   PubMed Web of Science ®Google Scholar
• Adyanthaya I, Kwon YI, Apostolidis E, Shetty K. Health benefits of apple phenolics from postharvest stages for potential type 2 diabetes management using in vitro models. J Food Biochem 2010;34:31–49.
   Web of Science ®Google Scholar
• Galeno DML, Carvalho RP, de Araújo Boleti AP, et al. Extract from Eugenia punicifolia is an antioxidant and inhibits enzymes related to metabolic syndrome. Appl Biochem Biotechnol 2014;172:311–24.
   PubMed Web of Science ®Google Scholar
• Giordanetto F, Pettersen D, Starke I, et al. Discovery of AZD2716: a novel secreted phospholipase A2 (sPLA2) inhibitor for the treatment of coronary artery disease. ACS Med Chem Lett 2016;7:884–9.
   PubMed Web of Science ®Google Scholar
• Sagawa N, Shikata T. Are all polar molecules hydrophilic? Hydration numbers of nitro compounds and nitriles in aqueous solution. Physical chemistry chemical physics. PCCP 2014;16:13262–70.
   PubMed Web of Science ®Google Scholar
• Tagami T, Yamashita K, Okuyama M, et al. Molecular basis for the recognition of long-chain substrates by plant α-glucosidases. J Biol Chem 2013;288:19296–303.
   PubMed Web of Science ®Google Scholar
• Lobo de Araujo A, Radvanyi F. Determination of phospholipase A2 activity by a colorimetric assay using a pH indicator. Toxicon 1987;25:1181–8.
   PubMed Web of Science ®Google Scholar
• Andrade-Cetto A, Becerra-Jiménez J, Cárdenas-Vázquez R. Alfa-glucosidase-inhibiting activity of some Mexican plants used in the treatment of type 2 diabetes. J Ethnopharmacol 2008;116:27–32.
   PubMed Web of Science ®Google Scholar
• Subramanian R, Asmawi MZ, Sadikun A. In vitro α-glucosidase and α-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide. J Pol Biochem Soc Committee Biochem Biophys 2008;55:391–8.
   Google Scholar